CA2106197A1 - Methode de traitement et de prevention de la toxicomanie - Google Patents

Methode de traitement et de prevention de la toxicomanie

Info

Publication number: CA2106197A1
Authority: CA; Canada
Prior art keywords: caring; substance; alkyl; individual; dependent
Prior art date: 1991-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002106197A

Other languages

English (en)

Inventor

Montford F. Piercey

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-26

Filing date

1992-04-13

Publication date

1992-10-27

1992-04-13 Application filed by Individual filed Critical Individual

1992-10-27 Publication of CA2106197A1 publication Critical patent/CA2106197A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 34
208000011117 substance-related disease Diseases 0.000 title claims abstract description 17
201000009032 substance abuse Diseases 0.000 title abstract description 19
231100000736 substance abuse Toxicity 0.000 title abstract description 13
239000000126 substance Substances 0.000 claims abstract description 47
230000001419 dependent effect Effects 0.000 claims abstract description 26
JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 claims abstract description 14
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 38
229960003920 cocaine Drugs 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 16
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
235000019441 ethanol Nutrition 0.000 claims description 10
241000208125 Nicotiana Species 0.000 claims description 9
235000002637 Nicotiana tabacum Nutrition 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 9
235000005607 chanvre indien Nutrition 0.000 claims description 8
244000261228 chanvre indien Species 0.000 claims description 8
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 6
229960002069 diamorphine Drugs 0.000 claims description 6
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 6
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 5
229940025084 amphetamine Drugs 0.000 claims description 5
-1 anion salts Chemical class 0.000 claims description 5
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
229940127240 opiate Drugs 0.000 claims description 4
239000000380 hallucinogen Substances 0.000 claims description 3
239000004081 narcotic agent Substances 0.000 claims description 3
235000019504 cigarettes Nutrition 0.000 claims description 2
229960004126 codeine Drugs 0.000 claims description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
229960005181 morphine Drugs 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 7
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 2
229960001252 methamphetamine Drugs 0.000 claims 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
229960000482 pethidine Drugs 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 3
229910052799 carbon Inorganic materials 0.000 description 14
125000001424 substituent group Chemical group 0.000 description 14
150000001721 carbon Chemical group 0.000 description 11
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
230000002265 prevention Effects 0.000 description 5
102000004659 Presynaptic Receptors Human genes 0.000 description 4
108010003717 Presynaptic Receptors Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
206010013654 Drug abuse Diseases 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000009223 counseling Methods 0.000 description 2
235000019788 craving Nutrition 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229960001797 methadone Drugs 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000001050 pharmacotherapy Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000905957 Channa melasoma Species 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
241000406799 Deto Species 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
101150071661 SLC25A20 gene Proteins 0.000 description 1
IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
239000000556 agonist Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
101150102633 cact gene Proteins 0.000 description 1
239000002775 capsule Substances 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000019506 cigar Nutrition 0.000 description 1
201000001272 cocaine abuse Diseases 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
239000000747 designer drug Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
230000001544 dysphoric effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
WCNLCIJMFAJCPX-UHFFFAOYSA-N pethidine hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 WCNLCIJMFAJCPX-UHFFFAOYSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000006308 propyl amino group Chemical group 0.000 description 1
NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Addiction (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002106197A 1991-04-26 1992-04-13 Methode de traitement et de prevention de la toxicomanie Abandoned CA2106197A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69323891A	1991-04-26	1991-04-26
US693,238		1991-04-26

Publications (1)

Publication Number	Publication Date
CA2106197A1 true CA2106197A1 (fr)	1992-10-27

Family

ID=24783880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002106197A Abandoned CA2106197A1 (fr)	1991-04-26	1992-04-13	Methode de traitement et de prevention de la toxicomanie

Country Status (5)

Country	Link
EP (1)	EP0581865A1 (fr)
JP (1)	JPH06506951A (fr)
AU (1)	AU1915192A (fr)
CA (1)	CA2106197A1 (fr)
WO (1)	WO1992019234A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2527328A1 (fr)	2008-04-01	2012-11-28	Abbott GmbH & Co. KG	Tétrahydroisoquinoléines, compositions pharmaceutiques les contenant et leur utilisation en thérapie
AR075442A1 (es)	2009-02-16	2011-03-30	Abbott Gmbh & Co Kg	Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US8877794B2 (en)	2010-08-13	2014-11-04	Abbott Laboratories	Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en)	2010-08-13	2015-06-02	AbbVie Deutschland GmbH & Co. KG	Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en)	2010-08-13	2014-09-30	Abbott Laboratories	Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en)	2010-08-13	2015-06-09	AbbVie Deutschland GmbH & Co. KG	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en)	2010-08-13	2014-11-11	Abbott Laboratories	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en)	2011-05-12	2016-04-12	AbbVie Deutschland GmbH & Co. KG	Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en)	2011-08-05	2014-10-07	AbbVie Deutschland GmbH & Co. KG	Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (zh)	2011-11-18	2014-08-27	艾伯维德国有限责任两合公司	N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
US9365512B2 (en)	2012-02-13	2016-06-14	AbbVie Deutschland GmbH & Co. KG	Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en)	2013-03-15	2017-05-16	Abbvie Inc.	Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en)	2013-03-15	2017-05-23	Abbvie Inc.	Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (fr)	2013-10-17	2015-04-23	AbbVie Deutschland GmbH & Co. KG	Dérivés d'aminochromane, d'aminothiochromane et d'amino-1,2,3,4-tétrahydroquinoléine, compositions pharmaceutiques contenant ceux-ci et leur utilisation thérapeutique
SG11201602935PA (en)	2013-10-17	2016-05-30	Abbvie Deutschland	Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL65501A (en) *	1981-05-08	1986-04-29	Astra Laekemedel Ab	1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
US4935429A (en) *	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
US4800204A (en) *	1987-05-07	1989-01-24	Mueller Peter S	Method of controlling tobacco use
US4994486A (en) *	1989-05-31	1991-02-19	Abbott Laboratories	Dopaminergic compounds

1992
- 1992-04-13 CA CA002106197A patent/CA2106197A1/fr not_active Abandoned
- 1992-04-13 JP JP4511382A patent/JPH06506951A/ja active Pending
- 1992-04-13 EP EP92911383A patent/EP0581865A1/fr not_active Withdrawn
- 1992-04-13 WO PCT/US1992/002808 patent/WO1992019234A2/fr not_active Ceased
- 1992-04-13 AU AU19151/92A patent/AU1915192A/en not_active Abandoned

Also Published As

Publication number	Publication date
AU1915192A (en)	1992-12-21
WO1992019234A3 (fr)	1993-01-07
WO1992019234A2 (fr)	1992-11-12
JPH06506951A (ja)	1994-08-04
EP0581865A1 (fr)	1994-02-09

Legal Events

Date	Code	Title	Description
1995-10-15	FZDE	Dead

Publication	Publication Date	Title
CA2106197A1 (fr)	1992-10-27	Methode de traitement et de prevention de la toxicomanie
Henderson	1988	Designer drugs: past history and future prospects
US12083090B2 (en)	2024-09-10	Methods of using low-dose doxepin for the improvement of sleep
US4499096A (en)	1985-02-12	Rapid method for interrupting the narcotic addiction syndrome
Papsun et al.	2019	The trouble with kratom: analytical and interpretative issues involving mitragynine
Angrist et al.	1978	Central nervous system stimulants: historical aspects and clinical effects
Himmelsbach	1942	Studies of the addiction liability of “Demerol”(D-140)
US20090042972A1 (en)	2009-02-12	Methods of using low-dose doxepin for the improvement of sleep
US20090042971A1 (en)	2009-02-12	Method of using low-dose doxepin for the improvement of sleep
BATTERMAN	1943	Clinical effectiveness and safety of a new synthetic analgesic drug, demerol
EP0563336A1 (fr)	1993-10-06	Composition pharmaceutique contenant de l'acide gamma-hydroxybutyrique ou sa lactone et utilisee dans le traitement de la toxicomanie et des troubles nutritionnels
US6858648B2 (en)	2005-02-22	Laetispicine and laetispicine analogues, methods of use and preparation
CA2118512C (fr)	2004-07-27	Agents utilises dans le traitement des toxicomanies
Chen et al.	1960	Pharmacologic studies of a new antitussive, alpha (dimethylaminoethyl)-ortho-chlorobenzhydrol hydrochloride (SL-501, Bayer B-186)
Beckett et al.	1962	2 The Testing and Development of Analgesic Drugs
EP0900082B1 (fr)	2001-11-07	Utilisation de la pyridyl-piperazine et de la pyrimydil-piperazine pour la manufacture d'un medicament pour le traitement de troubles lies a la toxicomanie
Nelson	1966	Medical problems associated with addiction to opioid drugs
Harris	1966	Analgetics–Strong and Weak
Gay et al.	1971	Some pharmacological perspectives on the opiate narcotics with special consideration of heroin
Campus	0	IBOGAINE (IBOGA TABERNANTHE) AS A POTENTIAL ANTI-ADDICTIVE TREATMENT IN THE PIPELINE: A REVIEW
Yang et al.	2018	Erycibe Alkaloid II
KR100491027B1 (ko)	2005-09-30	물질남용질환치료를위한피리딜-및피리미딜-피페라진
Nye	1988	The high affinity cannabinoid binding site in brain: a possible marijuana receptor
Misevic et al.	1964	The Use of Akineton for Parkinsonism
Morrone et al.	2016	21 Contribution of